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Abstract
Background: Recent studies showed that moderate consumption of red or white wines increased the chances of
breast cancer, while similar consumption of red wines, rich in trans-resveratrol (trans-R), decreased the rate of
prostate cancer. This prompted us to explore the role of various forms of R in cancer proliferation.
Results: Trans-R was found to be the most potent antiproliferative agent. Cis-R demonstrated somewhat less
potency compared to trans-R. Unlike cis-R and trans-R, dihydro-R exhibits moderate proliferative effect on
androgen-independent prostate cancer cell lines PC-3 and DU-145 at picomolar concentrations. At higher
concentrations, dihydro-R caused proliferation inhibition, similar to cis-R and trans-R. The proliferative effect of
dihydro-R at low concentrations can be reversed by trans-R which acts as a partial antagonist in the presence of
dihydro-R. Mixtures of dihydro-R and trans-R demonstrated complex non-monotonic cross-modulation activity
patterns.
Conclusions: Dihydro-R exhibits proliferative effects in androgen-independent prostate cancer cells at picomolar
and nanomolar concentrations. While the exact mechanism of these effects requires further evaluation, our
preliminary results point to hormone receptor modulation activity. We also observed strong cross modulation
between trans-R and dihydro-R at sub-picomolar concentrations. The role of dihydro-R in cancer proliferation
related to moderate consumption of red wine remains an open question because dihydro-R has a very complex
activity pattern in the presence of trans-R.
Background
The term “French Paradox” was introduced by S.
Renaud in the early 1990s to describe the low incidence
of heart disease and obesity among the French in con-
trast to their relatively high-fat diet [1]. It is widely
believed that consumption of red wine, rich in trans-
resveratrol (trans-R) and other dietary polyphenols, is
the primary cause of this paradox. Given the well-docu-
mented anticancer properties of trans-R, it is natural to
expect that the moderate consumption of red wine
might bring additional benefits of lower cancer rates,
especially the most frequent forms of cancer such as
breast and prostate cancer. However, recent studies
have unequivocally demonstrated that even moderate
consumption of red or white wines markedly increased
the chances of breast cancer [2-4], while moderate con-
sumption of red wine substantially decreased the rate of
prostate cancer [5]. It was also reported that moderate
consumption of white wine or beer does not affect pros-
tate cancer rate [5]. Although the alcohol content
should be considered as a prime factor responsible for
this intriguing disparity between the cancer types [2-5],
this unusual situation prompted us to further explore
the role of resveratrol (R) in prostate cancer
proliferation.
Like any food product, red wine contains a complex
mixture of structurally related organic compounds. One
of these compounds is R. The predominant trans-R
comes along with a lesser-known companion, cis-resver-
atrol (cis-R), and they are almost always present in red
wine together (Figure 1). We recently discovered [6]
that the GC-MS peak of cis-R was usually accompanied
by a close peak of another polyphenol having molecular
weight 2 Da higher than cis-R. Independent synthesis
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© 2011 Anisimova et alconfirmed that this peak is the peak of the third form of
R, dihydro-resveratrol (dihydro-R). Dihydro-R is a well-
known metabolite of trans-R [ 7 ] ,b u ti th a dn o tb e e n
identified in red wines before the study [6].
In our experiments dihydro-R demonstrated strong
proliferative properties in hormone-dependent cell lines
(such as MCF-7) at picomolar (10
-12 M) concentrations
[6]. The effect was not observed in cell lines without
estrogen receptors, and the proliferative effect could be
reversed by the action of estrogen antagonists, such as
the known breast cancer drug Tamoxifen. This is con-
sistent with the assumption that dihydro-R is a potent
phytoestrogen, even though the conformationally flexible
chemical structure of dihydro-R makes it a very unlikely
analog of 17b-estradiol and other synthetic nonsteroidal
estrogens such as diethylstilbestrol (DES) [6].
Given the preceding, it is reasonable to assume that
t h ep r e s e n c eo fdihydro-R in red wines could be par-
tially responsible for the difference observed between
breast cancer and prostate cancer in relation to moder-
ate wine consumption. To explore this further, we
initiated a comparative study of the biological effects of
the three forms of R found in red wines on two andro-
gen-independent human prostate cancer cell lines (PC-3
and DU-145) and one hormone-dependent breast cancer
cell line (MCF-7) in vitro. This paper presents the
results of our work.
Results and Discussions
To investigate the ability of trans-R, cis-R,a n ddihydro-
R to control the growth of PC-3 prostate cancer cells,
various concentrations of these compounds were added
to tumor cell cultures and then incubated for 48 h.
Figures 2 and 3 show the tumor cell viability after expo-
sure to these agents.
The cytotoxic effect of trans-R was observed at con-
centrations of 1 × 10
-7 to 1 × 10
-4 M. Similarly, the
cytotoxic effect of cis-R was observed at concentrations
1×1 0
-6 to 1 × 10
-4 M. The results indicated that trans-
R is somewhat more effective as an anticancer agent
than cis-R. Dihydro-R,i nc o n t r a s tt otrans-R and cis-R,
had a biphasic effect. At high concentrations (1 × 10
-5
to 1 × 10
-3 M), dihydro-R showed the typical for this
class of compounds decrease in the growth rate of
tumor cells. However, treatment with 1×10
-10 to 1 × 10
-
7 Mo fdihydro-R significantly increased the growth of
PC-3 prostate cancer cells (Figure 2).
Further comparative evaluation of the biological
activity of trans-R and dihydro-R was performed using
the DU-145 prostate cancer cell line. Again, trans-R
displayed only cytotoxic properties whereas dihydro-R
had a biphasic effect, similar to the one observed in
PC-3 cells. At high concentrations (1 × 10
-5 to 1 × 10
-
3 M), dihydro-R decreased the rate of growth of DU-
145 tumor cells. Treatment with low concentrations (1
×1 0
-10 to 1 × 10
-8 M) of dihydro-R significantly
increased the growth of DU-145 prostate cancer cells
(Figure 3).
The observed cytotoxic effects of both trans-R and cis-
R in androgen-independent prostate cancer cell lines are
in agreement with the previously reported data. Trans-R
is a known inhibitor of human prostate cancer cell
growth at concentrations of 1 × 10
-6 to 1 × 10
-4 M( e . g . ,
GI(50) = 2.41 × 10
-5 M, DU-145 [8]) depending on the
prostate cancer cell line and experimental conditions [9].
The biphasic action of the third form of R, dihydro-R,i n
O H
OH
OH
O H
OH
OH
O H
OH OH
Trans-R                                        Cis-R                                        Dihydro-R
Figure 1 Structures of trans-resveratrol (trans-R), cis-resveratrol (cis-R), and dihydro-resveratrol (dihydro-R) isomers.
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Figure 2 Biological activity of dihydro-R, trans-R and cis-R in
the PC-3 cell line.
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Page 2 of 6comparison with the better studied trans-R requires
further evaluation, especially in relation to estrogen
receptors [6] present in both the PC-3 and the DU-145
prostate cancer cell lines [10-14].
The biological effects of trans-R in androgen-indepen-
dent prostate cancer cell lines can be attributed to a
variety of specific molecular targets, including estrogen
and androgen receptors [15]. Unfortunately, the exact
mechanism of the hormone receptor-mediated activity
of trans-R is poorly understood because of the apparent
complexity of the underlying biological functions of
these receptors in prostate cancer cells. For example, it
is well documented that 17b-estradiol (E2) inhibits
growth of androgen-independent PC-3 cells [10] but sti-
mulates growth of androgen-dependent LNCaP cells,
presumably via its own receptor [16]. The situation is
even further complicated by the existence of two estro-
gen receptors (ERs), ER-a and ER-b, in prostate cancer
c e l l s[ 1 1 ] .A sar e s u l t ,g r o w t h of PC-3 cells, which have
both ER subtypes, can be effectively inhibited by estro-
gens as well as antiestrogens [17]. In contrast, DU-145
cells express only ER-b, and their growth can be inhib-
ited only by antiestrogens [11].
Given the convolution of hormone receptor functions
in prostate cancer cells [18], it could only be presented
as a working hypothesis that, similar to MCF-7 breast
cancer cells [6], the observed growth stimulation of PC-
3 and DU-145 cells by nanomolar concentrations of
dihydro-R can be attributed to the hormone receptor
modulation activity of this compound. A direct compari-
son between the three cell lines (MCF-7 [6], PC-3, and
DU-145, Figure 4) reveals substantial similarities in
dihydro-R biphasic proliferative action. As expected, the
proliferative effects are more pronounced in the “classic”
ER-a-dependent MCF-7 cells compared to PC-3 cells
(ER-a and ER-b) and then DU-145 cells (only ER-b).
Additional credence is given to our assumption that
dihydro-R is a hormone receptor modulator by the
recent observation that another dietary polyphenol with
a similar biological profile, genistein (Figure 5), also
exhibits biphasic behavior in the regulation of prostate
cancer cell growth [19]. It was reported that low (5 ×
10
-7 M) concentrations of genistein caused increased
proliferation of PC-3 cells whereas a pharmacologic
dose (5 × 10
-5 M) decreased proliferation. Estrogen sig-
naling is mentioned as one of the possible mechanisms
of this biphasic action [19] (genistein is a well-known
phytoestrogen [14,20,21]).
To explore our working hypothesis further, we evalu-
ated the cancer cell growth effects of dihydro-R in the
presence of trans-R. Trans-R is capable of acting as
both an estrogen and an antiestrogen [22-26], including
non-genomic action [25], but this compound by itself
does not significantly affect the growth of PC-3 prostate
cancer cells at concentrations below 1 × 10
-7 M. Our
experiments clearly demonstrated the interference
between dihydro-R and trans-R (Figure 6). In these
experiments trans-R acted as a dihydro-R antagonist at
low concentrations. The maximum antagonistic effect
was observed at nanomolar concentrations (1 × 10
-10 to
1×1 0
-8 M). Similar biphasic agonistic/antagonistic
properties of trans-R in MCF-7 cells in the presence of
E2 were reported previously [24].
Somewhat stronger interference between dihydro-R and
trans-R was observed in “classic” ER-a-dependent MCF-7
cells (Figure 7). As we mentioned previously, dihydro-R
proliferative action at very low concentrations was more
pronounced in the MCF-7 cell line than the PC-3 cell line
(Figure 4). As a result, cross-modulation effects of dihy-
dro-R and trans-R in MCF-7 cells were notable even at
sub-picomolar concentrations (1 × 10
-16 to 1 × 10
-13 M).
This modulation appeared to be non-monotonic and
showed a very complex concentration dependence pattern.
For example, maximum proliferation effects of a 1/1
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Figure 3 Biological activity of dihydro-R and trans-R in the DU-
145 cell line.
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Figure 4 Biological activity of dihydro-R in PC-3, DU-145, and
MCF-7 cell lines.
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Page 3 of 6mixture of dihydro-R and trans-R were observed at 1 ×
10
-14 and 1 × 10
-7 M concentrations, whereas intermediate
concentrations (1 × 10
-11 to 1 × 10
-9 M) showed little, if
any, proliferative activity (Figure 7). Non-monotonic dose
response is a well-documented feature of steroid hormone
receptors [27,28].
Experimental Section
Trans-R was obtained from Sigma (St. Louis, Missouri,
USA). Cis-R was prepared from trans-R by photoisome-
rization [29]. Dihydro-R was synthesized from trans-R
by catalytic hydrogenation according to [7,29]. The pur-
ity of the compounds was monitored by a combination
of high performance liquid chromatograpy,
1H nuclear
magnetic resonance (NMR) and
13CN M R .M C F - 7 ,a
human breast cancer cell line, and PC-3 and DU 145,
human prostate cancer cell lines, were obtained from
the American Type Culture Collection, Rockville, Mary-
land. Cell lines were cultured at 37°C in a 5% CO2
humidified atmosphere and maintained in RPMI-1640
(Sigma, USA) supplemented with 10% heat-inactivated
(56°C, 30 min) fetal calf serum (Hyclone Laboratories,
Logan, UK), 2 mM L-glutamine, and antibiotics (100
μg/ml penicillin sodium salt and 100 μg/ml streptomy-
cin sulfate [Sigma, USA], herein referred to as complete
medium [CM]). Resveratrol samples were dissolved in
dimethyl sulfoxide (DMSO) (Sigma, USA) at a concen-
tration of 200 mM, and diluted in culture medium just
before use. Tumor cells were harvested, counted, sus-
pended in CM, seeded into 96-well tissue culture plates
(Costar, France) in 200 μl/well at a concentration of 1 ×
10
5 cell/ml, and allowed to adhere overnight (required
for particular cell lines to be in log phase). After that,
CM was removed from sample wells. Compound sample
solutions in СМ were added to tumor cells. Final con-
centrations in sample wells amounted to 1 × 10
-15 -1×
10
-3 М. The plates were incubated at 37°C in a 5% CO2
humidified atmosphere for 48 h. Three replica wells
were used for controls and each compound concentra-
tion. The control samples contained DMSO concentra-
tions corresponding to target compound dilutions. Every
24 h cells underwent microscopy and were photo-
graphed with the help of an AxioVision 4 system (Zeiss,
Germany; see additional file 1). Cell viability assays were
performed using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphe-
nyltetrazolium bromide (MTT) reduction. After a 48 h
incubation of tumor cells (control or drug-treated),
MTT solution (5 mg/ml) was added to each well. A 4 h
incubation at 37° C was stopped by the addition of
100 μl of DMSO. The absorbances of the samples were
measured on a microplate reader Multiscan MS
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Figure 6 Biological activity of dihydro-Ra n dtrans-Rm i x t u r e s
(1/1; 10/1; 1/10) in PC-3 cells.
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Figure 7 Biological activity of trans-Ra n ddihydro-Rm i x t u r e s
(1/1; 1/10; 10/1) in MCF-7 cells line.
O H
OH
O
OH
O
O H
H
H
OH
H
Genistein 17EEstradiol (E2)
Figure 5 Structures of genistein and E2.
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Page 4 of 6(Labsystem, Finland) at 540 nm after 30 min incubation
at 37°C. Cell viability was expressed as a relative viability
of tumor cells (percent of control cultures incubated
with medium only) and was calculated as follows: rela-
tive viability = [(Ae - Ab)/(Ac - Ab)] × 100, where Ab is
the background absorbance, Ae is the experimental
absorbance, and Ac is the absorbance of untreated con-
trols. The Statistica software package, version 6.0 (Stat-
Soft) was used for statistical analysis.
Conclusions
We demonstrated that the biphasic proliferative effects
of dihydro-R at picomolar and nanomolar concentra-
tions are not limited to hormone-dependent breast can-
cer cells but also present, albeit in a reduced scale, in
androgen-independent prostate cancer cells. While the
exact mechanism of these effects requires further eva-
luation, our preliminary results point to hormone recep-
tor modulation activity. A significant similarity exists
between the phytoestrogens genistein and dihydro-R.
We also observed strong cross modulation between
trans-R and dihydro-R, which is noticeable even at sub-
picomolar concentrations. The role of dihydro-R in
breast cancer and prostate cancer proliferation related
to moderate consumption of red wine remains an open
question because dihydro-R exhibits proliferative activity
in both prostate and breast cancer cells at low concen-
trations and has a very complex activity pattern in the
presence of trans-R.
Note Added in Proof
The anti-cancer properties of trans-R go beyond direct
growth inhibition of cancer cells. It is known that nat-
ural killer (NK) cells, such as mononuclear leukocytes
(ML), are capable to kill tumor cells. We subsequently
studied immunotropic activity of trans-R (Table 1, addi-
tional file 2). It was found that 10
-6 Mo ftrans-R signifi-
cantly activated lysis of К-562 cells by ML compared to
intact ML: 61 ± 6.8% vs. 46 ± 5.8% for К-562/ML cell
ratio 1:10; and 53 ± 8.7% vs. 26 ± 7.3% for К-562/ML
cell ratio 1:5.
Our results are consistent with the general trends
observed in the previous in vitro studies [30]. The
authors [30] reported that in vitro exposure to trans-R
produced a biphasic effect on the anti-CD3/anti-CD28-
induced development of both IFN-gamma-IL2 and -IL4-
producing CD8+ and CD4+ T-cells. Trans-R was found
to induce a significant enhancement of NK cell cytotoxic
activity at low concentrations and to induce suppression
at high concentrations.
Additional material
Additional file 1: Cytotoxic activity of dihydro-R and trans-R
mixtures. Microscopic evaluation of the cytotoxic activity of dihydro-R
and trans-R mixtures in MCF-7 and PC-3 cell lines.
Additional file 2: Immunotropic activity of trans-R. Microscopic
evaluation of the immunotropic activity of trans-R in К-562 cell line.
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